Dr. Drug Rep tells all

We've seen the numbers and read the surveys. Now, we can hear the story straight from the horse's, er, doctor's mouth. An M.D. and former speaker-on-behalf-of-a-drug tells his story in the New York Times Magazine, and it's an illuminating, behind-the-scenes look at how Dr. Daniel Carlat (photo) became Dr. Drug Rep.

First, the reel-in: a flattering call from Wyeth, which wanted Dr. Carlat to spread the (good) word about Effexor XR, and an expense-paid trip to Manhattan for speakers' education. Second, the spiel: Soon, Dr. Carlat was delivering his talk all over the Boston area. Third, the prick of conscience: Lo and behold, Dr. Carlat realizes he's been spinning the data in Wyeth's favor. You'll have to read the article for the rest.

One interesting tidbit in the article was the fact that drug makers don't have access to doctors' prescribing histories without the help of the American Medical Association. Pharmacy data typically IDs the prescriber by DEA number. Only by buying a list from the AMA can data-mining companies link the prescriptions to the doctors' names--and then resell the info to pharma companies.

- check out the article from The New York Times

Related Articles:
Top Lilly exec plays secret sales agent. Report
No freebies? No entry for pharma reps. Report
Wyeth gets OK to use Effexor XR for panic disorder. Report
Hospital to ban pharma rep freebies. Report

Suggested Articles

In a first, the FDA and Indian oversight agencies worked together to block illegal drugs from entering the U.S. 

The agency has granted Tecentriq a priority review in previously untreated NSCLC, setting up the Roche drug for an approval decision by June 19.

Warren Buffett's Berkshire Hathaway has built a $192 million stake in Biogen, a risky investment considering aducanumab's uncertain future.